Inhibitors of the farnesoid x receptor and uses in medicine

US10233209B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• The Penn State Research Foundation · US

Inventors

• Frank J. Gonzalez · Bethesda, US
• Changtao Jiang · Beijing, CN
• Cen Xie · Rockville, US
• Andrew D. Patterson · Bethesda, US
• Fei Li · Austin, US
• James B. Mitchell · Damascus, US
• Shantu Amin · Union City, US
• Dhimant H. Desai · Mechanicsburg, US

Key dates

• Filing date: Dec 6, 2016
• Grant date: Mar 19, 2019
• Expiry date: Dec 6, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07J41/0066
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are inhibitors of the farnesoid X receptor, for example of formula (I), wherein R1, R2, R4, X, Y, Z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non-alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, a method of method of inhibiting a farnesoid X receptor in a mammal, and a method of treating or preventing obesity in a mammal.